01 2023 01 16 BDD Poster guselkumab Ra S

Exploring the exposure-response relationship of Guselkumab in chronic plaque Psoriasis: Preliminary results

Rani Soenen

Voir PDF

02 2023 01 11 BDD Poster Lisa S portrait

Blocking Interleukin-17 in Psoriasis: Real-world experience from the PsoPlus cohort

Lisa Schots

Voir PDF

03 Prevalence of comorbidities in the UZ Leuven psoriasis cohort

Psoriasis in the Belgian population: Prevalence of comorbidities

Heleen Cokelaere
Tom Hillary

Voir PDF

04 BDD2023 Poster 4

Nectin-4-directed oncologic therapies, what to expect as a dermatologist?

Evelyn Meulewaeter
Linda Temmerman

Voir PDF

05 BDD2023 Poster PGD UZL

The impact of the COVID-19 pandemic on the incidence and thickness of cutaneous melanoma in Belgium

P.G. Demaerel

Voir PDF

06 Poster BDD

A cohort study of older adults receiving Mohs micrographic surgery for a facial basal cell carcinoma: should we waive MMS in certain patients?

Laura Van Coile

Voir PDF

07 Poster BDD190123

Vitamin D receptor expression in cutaneous melanoma tissue: prognostic properties and influencing factors

Julie De Smedt

Voir PDF

08 poster BDD2023 08

Acute pancreatitis induced by topical isotretinoin, an unprecedented association

Thomas Damsin

Voir PDF

09 BDD poster Prognostic Value Disease Activity Signs Vitiligo n9

Prognostic value of the Vitiligo disease activity signs

Liesbeth Delbaere

Voir PDF

10 BDD 2023 POETYK BSA s PG Ax BSA Encore Poster Bristol Myers Squibb Lambert

Deucravacitinib, an oral, selective, Allosteric Tyrosine Kinase 2 Inhibitor, versus placebo and Apremilast in moderate to severe plaque Psoriasis: Analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials

Jo Lambert

Voir PDF

11 Key secondary endpoints at Month 12 3rd Interim BDD 2023 Final draft 18 Jan2023

Initial report on the month 12 results from the Psoriasis Study of Health Outcomes (PSoHO) for patients with moderate-to-severe Psoriasis treated with biologics in the real-world setting

L. Ghys

Voir PDF

12 Multiple CBA global Ps O improv in all 3 measures BDD 2023 18 Jan2023

Ixekizumab demonstrates comprehensive Psoriasis clearance in patients with moderate-to-severe Psoriasis with scalp, nail, and/or palmoplantar involvement: UNCOVER-1, -2 trials through 5 years

L. Ghys

Voir PDF

13 Poster BDD 2023 nr13 REDISCOVER Final Version Hillary et al

Disease severity and implementation of the Belgian T2T guidelines in moderate-to-severe plaque Psoriasis: Results from the Belgian REDISCOVER study

L.F.E. Ghys

Voir PDF

14 Poster number 14 BDD 2023 JAHO JAIR Trajectories Final Draft 20 Jan2023

Trajectories for scalp hair regrowth in patients with severe Alopecia Areata treated with Baricitinib

L. Ghys

Voir PDF

15 Poster number 15 BDD 2023 JAHN 2yr Qo L Final draft 20 Jan 2023

Maintained improvement in patient rated outcomes with Baricitinib 4-mg in adults with moderate to severe Atopic Dermatitis who were treated for up to 104 weeks in randomised controlled trials

L. Ghys

Voir PDF

16 Poster number 16 BDD 2023 AD Annual Safety 2022 Final draft 20 Jan 2023

Safety of Baricitinib for the treatment of Atopic Dermatitis over a median of 1.6 and up to 3.9 years treatment: An updated integrated analysis of 8 clinical trials

L. Ghys

Voir PDF

17 BDD 2023 SUNNY Wk16 Poster 17

Secukinumab in moderate to severe Hidradenitis Suppurativa: Primary endpoint analysis from the SUNSHINE and SUNRISE phase 3 trials

Farida Benhadou

Voir PDF

Lire la suite?

Devenez membre de la Société Royale Belge de Dermatologie et Vénérologie (SRBDV) et l'Union Professionnelle Belge de Dermatologie et Vénérologie (UPBDV)) !

Votre cotisation vous donne droit à une série d’avantages, comme un accès illimité à la partie 'members only' de ce site web, mais aussi une inscription fortement réduite aux Belgian Dermatology Days (BDD) qui est organisé annuellement.
En plus l’accès au site web de l'Union Professionnelle et des newsletters envoyées par mail pour les nouvelles informations importantes. Il y a aussi une importante réduction de votre cotisation pour les listes des allergènes sur le site des allergies de contact. et une assurance professionnelle en responsabilité civile qui a été développée spécifiquement pour notre discipline.